Status:
COMPLETED
Implication of Coronary Artery Disease Burden and Pattern in Ischemia-causing Vessels With PCI
Lead Sponsor:
Shanghai Zhongshan Hospital
Collaborating Sponsors:
China National Center for Cardiovascular Diseases
Conditions:
Coronary Artery Disease
Myocardial Ischemia
Eligibility:
All Genders
18+ years
Brief Summary
Ischemia-guided revascularization is the cornerstone of contemporary management of coronary artery disease (CAD). Coronary physiological assessment is advocated in the catheter laboratory to guide per...
Detailed Description
Ischemia-guided revascularization is the cornerstone of contemporary management of coronary artery disease (CAD). Coronary physiological assessment is advocated in the catheter laboratory to guide per...
Eligibility Criteria
Inclusion
- Patients with at least one vessel with measurable QFR≤ 0.80;
- PPG index can be calculated from virtual QFR pullback curve;
- The patient is willing to comply with specified follow-up evaluations;
- Patients who agree to accept the follow-up visits.
Exclusion
- Culprit vessels for ACS myocardial infarction;
- Pregnant or nursing patients and those who plan pregnancy in the period up to 1 year following index procedure;
- Patient has other medical illness (e.g., cancer, known malignancy, congestive heart failure, organ transplant recipient or candidate) or known history of substance abuse (alcohol, cocaine, heroin etc.) that may cause non-compliance with the protocol, confound the data interpretation or is associated with a limited life expectancy (i.e., less than 1 year);
- Patient has a known hypersensitivity or contraindication to aspirin, heparin, clopidogrel/ticlopidine, stainless steel alloy, cobalt chromium, rapamycin, styrene-butylenes-styrene or poly-lactic acid (PLA) polymer, and/or contrast sensitivity that cannot be adequately pre-medicated;
- Any significant medical condition which in the Investigator's opinion may interfere with the patient's optimal participation in the study;
- Currently participating in another investigational drug or device study or patient in inclusion in another investigational drug or device study during follow-up.
Key Trial Info
Start Date :
November 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2021
Estimated Enrollment :
1003 Patients enrolled
Trial Details
Trial ID
NCT04665466
Start Date
November 1 2013
End Date
February 1 2021
Last Update
April 2 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
180 Fenglin Road
Shanghai, China, 200032